… Progression-free survival (PFS) was defined as the time from the initiation of anti-PD-1/PD-L1
therapy until evidence of disease progression or death. Overall survival (OS) was defined …

… non-small cell lung cancer (NSCLC) … disease progression. Conventional practice would
be to switch treatments to second-line therapy. However, continuing TKIs beyond progression is …

… Furthermore, improvement in immune markers accompanied clinical improvement, whereas
decline in the same markers was associated with disease progression. Tumor vaccines …

… dramatic progression group demonstrated the shortest disease … The gradual progression
group showed the longest disease … The local progression group displayed moderate disease …

… new or recurrent sites of disease, and the rate of progression. Past studies addressing this
… In this series, LAT extended the time to further disease progression. In a few cases, LAT was …

BACKGROUND: The authors studied growth and progression of untreated nonsmall cell
lung cancer (NSCLC) by comparing diagnostic and radiotherapy (RT) planning …

… smoking after diagnosis of lung cancer affects the risk for disease progression and mortality.
… with lung cancer and 1.76 million died of this disease, making it the leading cause of cancer …

… ) or have stable disease and have no disease progression. Continuation maintenance therapy
… ) may be continued until evidence of disease progression or unacceptable toxicity, as per …

… association of disease progression with HRQoL. In metastatic non–small cell lung cancer, an
… significant worsening in HRQoL upon disease progression, and a small retrospective study …

… : arm A (7 patients) included patients with disease progression within 3 months; arm B (23
patients), those with disease progression more than 3 months after treatment. No objective …